CommercialMarch 1, 2019
Clinical criteria updates for specialty pharmacy
On December 1, 2018, we introduced the new clinical criteria page for injectable, infused or implanted drugs. Effective for dates of service on and after March 1, 2019, the following new clinical criteria will be included in our clinical criteria review process. The drugs that require prior authorization will continue to require prior authorization notification with AIM.
Existing precertification requirements have not changed for the specific clinical criteria below. While there are no material changes, the document number and online location has changed. To access the clinical criteria information please click here. The table below will assist you in identifying the new document number for the clinical criteria that corresponds with the previous Clinical Guideline/Medical Policy.
Pre-service clinical review of these specialty pharmacy drugs will be managed by AIM Specialty Health® (AIM), a separate company.
Clinical Guideline/ Medical Policy |
Clinical Criteria Document Number |
Clinical Criteria Name |
Drug(s) |
HCPCS or CPT Code(s) |
CG-DRUG-29 |
ING-CC-0006 |
Hyaluronan Injections |
Durolane, Euflexxa, Gel-One, Gen-Syn, GenVisc, Hyalgan, Hymovis, Monovisc, Orthovisc, Supartz/FX, Synvisc/-One, TriVisc, Visco-3 |
J7318, J7320 , J7321, J7322, J7323, J7324 , J7325, J7326, J7327, J7328, J7329 |
DRUG.00015 |
ING-CC-0007 |
Synagis (palivizumab) |
Synagis |
90378 |
DRUG.00031 |
ING-CC-0008 |
Testopel (testosterone subcutaneous implant) |
Testosterone implant |
S0189 |
DRUG.00074 |
ING-CC-0009 |
Lemtrada (alemtuzumab) |
Lemtrada |
J0202 |
DRUG.00078 |
ING-CC-0010 |
Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors |
Praluent, Repatha |
J3490 , J3590 |
DRUG.00095 |
ING-CC-0011 |
Ocrevus (ocrelizumab) |
Ocrevus |
J2350 |
DRUG.00099 |
ING-CC-0012 |
Brineura (cerliponase alfa) |
Brineura |
J0567 |
DRUG.00116 |
ING-CC-0013 |
Mepsevii (vestronidase alfa) |
Mepsevii |
J3490 |
CG-DRUG-03 |
ING-CC-0014 |
Beta Interferons and Glatiramer Acetate for Treatment of Multiple Sclerosis |
Avonex, Plegridy, Rebif, Betaseron, Extavia, Copaxone, Glatopa |
J1595, J1826, J1830, J3490, Q3027, Q3028 |
CG-DRUG-27 |
ING-CC-0017 |
Xiaflex (clostridial collagenase histolyticum) injection |
Xiaflex |
J0775 |
CG-DRUG-28 |
ING-CC-0018 |
Lumizyme (alglucosidase alfa) |
Lumizyme |
J0221 |
CG-DRUG-43 |
ING-CC-0020 |
Tysabri (natalizumab) |
Tysabri |
J2323 |
CG-DRUG-54 |
ING-CC-0021 |
Fabrazyme (agalsidase beta) |
Fabrazyme |
J0180 |
CG-DRUG-55 |
ING-CC-0022 |
Vimizim (elosulfase alfa) |
Vimizim |
J1322 |
CG-DRUG-56 |
ING-CC-0023 |
Naglazyme (galsulfase) |
Naglazyme |
J1458 |
CG-DRUG-57 |
ING-CC-0024 |
Elaprase (idursufase) |
Elaprase |
J1743 |
CG-DRUG-58 |
ING-CC-0025 |
Aldurazyme (laronidase) |
Aldurazyme |
J1931 |
CG-DRUG-73 |
ING-CC-0027 |
Denosumab agents |
Prolia, Xgeva |
J0897 |
CG-DRUG-84 |
ING-CC-0028 |
Benlysta (belimumab) |
Benlysta |
J0490 |
CG-DRUG-88 |
ING-CC-0029 |
Dupixent (dupilumab) |
Dupixent |
J3490, J3590 |
CG-DRUG-89 |
ING-CC-0030 |
Implantable and ER Buprenorphine Containing Agents |
Probuphine, Sublocade |
J0570, J3490 , Q9991, Q9992 |
CG-DRUG-103 |
ING-CC-0032 |
Botulinum Toxin |
Botox, Xeomin, Dysport, Myobloc |
J0585, J0586, J0587 , J0588 , J0585, J0586 , J0587 , J0588 |
CG-DRUG-104 |
ING-CC-0033 |
Xolair (omalizumab) |
Xolair |
J2357 |
CG-DRUG-108 |
ING-CC-0035 |
Duopa (carbidopa and levodopa enteral suspension) |
Duopa |
J7340 |
CG-DRUG-111 |
ING-CC-0037 |
Kanuma (sebelipase alfa) |
Kanuma |
J2840 |
CG-DRUG-112 |
ING-CC-0038 |
Human Parathyroid Hormone Agents |
Tymlos |
J3490 |
DRUG.00013 |
ING-CC-0039 |
GamaSTAN [(immune globulin (human)] |
GamaSTAN. GamaSTAN S/D |
J1460, J1560 |
DRUG.00027 |
ING-CC-0040 |
Prialt (ziconotide) |
Prialt |
J2278 |
DRUG.00050 |
ING-CC-0041 |
Soliris (eculizumab) |
Soliris |
J1300 |
DRUG.00077 |
ING-CC-0042 |
Monoclonal Antibodies to Interleukin-17 |
Cosentyx (secukinumab), Siliq (brodalumab), Taltz (ixekizumab) |
C9399, J3490, J3590 |
DRUG.00080 |
ING-CC-0043 |
Monoclonal Antibodies to Interleukin-5 |
Cinqair (reslizumba), Fasenra (benralizumab), Nucala (mepolizumab) |
J0517, J2182, J2786 |
DRUG.00081 |
ING-CC-0044 |
Exondys 51 (eteplirsen) |
Exondys 51 |
J1428 |
DRUG.00086 |
ING-CC-0045 |
Increlex (mecasermin) |
Increlex |
J2170 |
DRUG.00090 |
ING-CC-0046 |
Zinplava (bezlotoxumab) |
Zinplava |
J0565 |
DRUG.00096 |
ING-CC-0047 |
Trogarzo (ibalizumab-uiyk |
Trogarzo |
J1746 |
DRUG.00104 |
ING-CC-0048 |
Spinraza (nusinersen) |
Spinraza |
J2326 |
DRUG.00108 |
ING-CC-0049 |
Radicava (edaravone) |
Radicava |
J1301 |
DRUG.00111 |
ING-CC-0050 |
Monoclonal Antibodies to Interleukin-23 |
Ilumya, Tremfya |
J1628, J3245 |
CG-DRUG-08 |
ING-CC-0051 |
Enzyme Replacement Therapy for Gaucher Disease |
Cerezyme, Elelyso, Vpriv |
J1786 , J3060 , J3385 |
CG-DRUG-44 |
ING-CC-0057 |
Krystexxa (pegloticase) |
Krystexxa |
J2507 |
CG-DRUG-45 |
ING-CC-0058 |
Octreotide Agents |
Sandostatin, Sandostatin LAR Depot |
J2353 , J2354 |
CG-DRUG-61 |
ING-CC-0061 |
GnRH Analogs for the treatment of non-oncologic indications |
Zoladex, Supprelin LA, Lupron Depot/Depot-Ped, Lupaneta Pack, Synarel Nasal Spray, Triptodur |
C9399, J3490, J1675, J1950, J3315, J3316, J9202 , J9217, J9218 , J9225, J9226 , J3490 |
CG-DRUG-69 |
ING-CC-0063 |
Stelara (ustekinumab) |
Stelara |
J3357, J3358 |
CG-DRUG-74 |
ING-CC-0064 |
Interleukin-1 Inhibitors |
Arcalyst, Ilaris |
J2793, J0638 |
CG-DRUG-93 |
ING-CC-0066 |
Monoclonal Antibodies to Interleukin-6 |
Actemra, Kevzara |
J3262, C9399 , J3490 , J3590 |
CG-DRUG-82 |
ING-CC-0067 |
Prostacyclin Infusion and Inhalation Therapy |
Flolan, Remodulin, Tyvaso, Veletri, Ventavis |
J1325, J3285, J7686, K0455 , Q4074, S0155 , S9347 |
CG-DRUG-83 |
ING-CC-0068 |
Growth hormone |
Genotropin, Humatrope, Norditropin, Nutropin AQ, Omnitrope, Saizen, Serostim, Zomacton, Zorbtive |
J2940 , J2941 , Q0515 , S9558 |
CG-DRUG-85 |
ING-CC-0069 |
Egrifta (tesamorelin) |
Egrifta |
J3490 |
CG-DRUG-86 |
ING-CC-0070 |
Jetrea (ocriplasmin) |
Jetrea |
J7316 |
CG-DRUG-87 |
ING-CC-0071 |
Entyvio (vedolizumab) |
Entyvio |
J2503 , C9257, J9035, Q5107 , J2778, J0178 |
CG-DRUG-92 |
ING-CC-0073 |
Alpha-1 Proteinase Inhibitor Therapy |
Aralast, Glassia, Prolastin-C, Zemaira |
J0256, J0257 |
CG-DRUG-94 |
ING-CC-0075 |
Rituxan (rituximab) for Non-Oncologic Indications |
Rituxan |
J9311 |
CG-DRUG-95 |
ING-CC-0076 |
Nulojix (belatacept) |
Nulojix |
J0485 |
CG-DRUG-105 |
ING-CC-0078 |
Orencia (abatacept) |
Orencia |
J0129 |
CG-DRUG-109 |
ING-CC-0079 |
Strensiq (asfotase alfa) |
Strensiq |
J3490 |
PUBLICATIONS: March 2019 Anthem Connecticut Provider Newsletter
To view this article online:
Or scan this QR code with your phone